※一部利用できない機能があります
Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era
- フォーマット:
- 論文
- 責任表示:
- Takamatsu, Hiroyuki ; Honda, Sumihisa ; Miyamoto, Toshihiro ; Yokoyama, Kenji ; Hagiwara, Shotaro ; Ito, Toshiro ; Tomita, Naoto ; Iida, Shinsuke ; Iwasaki, Toshihiro ; Sakamaki, Hisashi ; Suzuki, Ritsuro ; Sunami, Kazutaka
- 言語:
- 英語
- 出版情報:
- 日本癌学会 = The Japanese Cancer Association / Blackwell Publishing Ltd, 2015-02-01
- 著者名:
- 掲載情報:
- Cancer science
- ISSN:
- 1349-7006
- 巻:
- 106
- 通号:
- 2
- 開始ページ:
- 179
- 終了ページ:
- 185
- バージョン:
- publisher
- 概要:
- We evaluated the clinical significance of prognostic factors including the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma (MM) who underwent upfront single autologous stem cell transplantation (ASCT). We categorized patients into two treatment cohorts: pre-novel agent era (1995-2006) and novel agent era (2008-2011). The combined percentage of pre-ASCT … complete response and very good partial response cases (463 of 988, 47%) significantly increased during the novel agent era compared with the pre-novel agent era (164 of 527, 31%; P < 0.0001). The 2-year overall survival (OS) rate of 87% during the novel agent era was a significant improvement relative to that of 82% during the pre-novel agent era (P = 0.019). Although significant differences in OS were found among ISS stages during the pre-novel agent era, no significant difference was observed between ISS I and II (P = 0.107) during the novel agent era. The factors independently associated with a superior OS were female gender (P = 0.002), a good performance status (P = 0.024), lower ISS (P < 0.001), pre-ASCT response at least partial response (P < 0.001) and ASCT during the novel agent era (P = 0.017). These results indicate that the response rate and OS were significantly improved, and the ISS could not clearly stratify the prognoses of Japanese patients with MM who underwent upfront single ASCT during the novel agent era. © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. 続きを見る
- URL:
- http://hdl.handle.net/2297/43450
類似資料:
Japanese Cancer Association / Blackwell Publishing Ltd |
Japanese Cancer Association 日本癌学会 / Wiley Open Access |
金沢大学, 金沢大学21世紀COEプログラム「環日本海域の環境計測と長期・短期変動予測」 |
The Japan Society for Analytical Chemistry = 日本分析化学会 (JSAC) |
日本内科学会 = Japanese Society of Internal Medicine | |
10
論文
Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity
Pharmaceutical Society of Japan = 日本薬学会 | |
Medical and Pharmaceutical Society for WAKAN-YAKU = 和漢医薬学会 | |
Springer New York |